SSB 1138: Relating to a review of anti-obesity medications by the department of health and human services and the department of administrative services for purposes of the medical assistance program and health insurance plans for public employees

What it does

This bill relates to the department of health and human services (HHS) and the department of administrative services (DAS) review of anti-obesity medication for purposes of the medical assistance program and health insurance plans established pursuant to Code chapter 509A for public employees. The bill requires HHS and DAS to review anti-obesity medications, including GLP-1 agonists, for effectiveness, comorbidities, cost savings, and eligibility requirements as described in the bill. HHS and DAS shall submit a report to the general assembly by January 5, 2026, containing HHS’s and DAS’s findings and proposed eligibility requirements.

Senate subcommittee · named February 18, 2025

• Sen. Mike Klimesh (R) · mike.klimesh@legis.iowa.gov
• Sen. Sandy Salmon (R) · sandy.salmon@legis.iowa.gov
• Sen. Zach Wahls (D) · zach.wahls@legis.iowa.gov

Lobbying · 2 for, 0 against

For: American Diabetes Association; Eli Lilly & Co.

In plain words

1. February 18, 2025Filed in the Senate and sent to the Health and Human Services committee
2. February 18, 2025Senate subcommittee named: Klimesh, Salmon and Wahls
3. February 20, 2025Subcommittee recommended passing it with changes
4. March 5, 2025Approved by the Senate committee, and given a new number: SF 552